Tritace in renal disease

Tritace (ramipril) is now licensed for the treatment of incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria, manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor, or manifest glomerular non-diabetic nephropathy as defined by macroproteinuria ≥3g/day.

View Tritace drug record

Further information: Sanofi-aventis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more